KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ionis Pharmaceuticals (IONS) Other Gross PP&E Adjustments (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Other Gross PP&E Adjustments for 17 consecutive years, with -$235.1 million as the latest value for Q1 2026.

  • For Q1 2026, Other Gross PP&E Adjustments fell 47.59% year-over-year to -$235.1 million; the TTM value through Mar 2026 reached -$235.1 million, down 47.59%, while the annual FY2025 figure was -$74.0 million, 40.92% down from the prior year.
  • Other Gross PP&E Adjustments hit -$235.1 million in Q1 2026 for Ionis Pharmaceuticals, down from -$74.0 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at -$52.5 million in Q4 2024 and bottomed at -$242.0 million in Q3 2025.
  • Average Other Gross PP&E Adjustments over 5 years is -$160.1 million, with a median of -$168.2 million recorded in 2024.
  • Year-over-year, Other Gross PP&E Adjustments tumbled 510.94% in 2022 and then surged 53.58% in 2023.
  • Ionis Pharmaceuticals' Other Gross PP&E Adjustments stood at -$194.2 million in 2022, then soared by 53.58% to -$90.1 million in 2023, then soared by 41.73% to -$52.5 million in 2024, then crashed by 40.92% to -$74.0 million in 2025, then plummeted by 217.63% to -$235.1 million in 2026.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$235.1 million, -$74.0 million, and -$242.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.